Journal Browser

► Journal Browser

Special Issue Editors

Dr. Laura Marinela Ailioaie

Department of Medical Physics, Alexandru Ioan Cuza University, 11 Carol I Boulevard, 700506 Iasi, Romania
Interests: nanomedicine; PDT; PTT; PIT; photobiomodulation; nanorobots

Prof. Dr. Michael R. Hamblin

E-Mail Website1 Website2
Guest Editor

Distinguished Visiting Professor, Laser Research Centre, University of Johannesburg, Johannesburg, South Africa
Interests: photomedicine; photobiomodulation; photodynamic therapy; new photosensitizers; antimicrobial photodynamic inactivation; nanomedicine; drug delivery
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. René-Jean Bensadoun

E-Mail Website
Guest Editor

Centre de Haute Energie, 10 Bd Pasteur, 06000 Nice, France
Interests: photobiomodulation; radiation therapy; supportive care in cancer; head and neck cancer

Dr. Constantin Ailioaie

E-Mail Website
Guest Editor

Department of Medical Physics, Alexandru Ioan Cuza University, 11 Carol I Boulevard, 700506 Iasi, Romania
Interests: photobiomodulation; pain; rehabilitation; pediatrics; nanomedicine; photo-immunotherapy

Special Issue Information

Dear Colleagues,

This Special Issue welcomes the submission of original research manuscripts or reviews in the area of pharmaceutical sciences and the latest combined integrative therapies such as photothermal, photodynamic and photo-immunotherapy (PTT, PDT, and PIT) and other antimicrobial nanomedicine-related applications, together with light-triggered multifunctional nanoplatforms loaded with novel nanodrugs as smart solutions in synergistic nanomedicine of the future. We invite all of you to contribute interesting papers and cutting-edge results in this exciting research and medical field, and open up additional avenues to accelerate the advancement of innovative approaches for multi-target tumor management, so as to meet the critical needs of patients and redefine cancer therapy. We aim to collect and introspect high-tech medical applications in molecular and cellular research of photosensitizers, new light and laser energy delivery systems, and nanorobots and nanomedicines, as well as the features of photomedicine integration of PTT, PDT, and PIT as molecular-targeted therapies in immuno-oncology, from bench to bedside, as well as other antimicrobial nanomedicine-related applications.

The incredible nanomedical breakthroughs revealed in this Special Issue are expected to bring cancer patients new hope for a longer life expectancy or even a cure. It presents remarkable innovations that can overcome major challenges in cancer therapy, as well as other antimicrobial nanomedicine-related applications.

We plan to receive submissions until 31 July 2024. Manuscripts will be published online on an ongoing basis after being processed.

Dr. Laura Marinela Ailioaie
Prof. Dr. Michael R. Hamblin
Prof. Dr. René-Jean Bensadoun
Dr. Constantin Ailioaie
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

antimicrobial
cancer therapy
tumor recurrence and metastasis
photomedicine
photobiomodulation
new photosensitizers
nanotechnology
nanomedicine
photothermal therapy
photodynamic therapy
photo-immunotherapy
clinical applications of PTT, PDT, and PIT
immunogenic cell death
drug design
drug delivery systems
light-triggered multifunctional nanoplatforms
controlled release
unmet clinical needs
nanotherapies targeting mitochondria
nanoparticles
nanosystems
nanorobots
nanocarriers
radiation therapy

Published Papers (1 paper)

Review

46 pages, 4899 KiB

Open AccessReview

Lipid Nanocarriers-Enabled Delivery of Antibiotics and Antimicrobial Adjuvants to Overcome Bacterial Biofilms

by Anam Ahsan, Nicky Thomas, Timothy J. Barnes, Santhni Subramaniam, Thou Chen Loh, Paul Joyce and Clive A. Prestidge

Pharmaceutics 2024, 16(3), 396; https://doi.org/10.3390/pharmaceutics16030396 - 14 Mar 2024

Viewed by 1660

Abstract

The opportunistic bacteria growing in biofilms play a decisive role in the pathogenesis of chronic infectious diseases. Biofilm-dwelling bacteria behave differently than planktonic bacteria and are likely to increase resistance and tolerance to antimicrobial therapeutics. Antimicrobial adjuvants have emerged as a promising strategy to combat antimicrobial resistance (AMR) and restore the efficacy of existing antibiotics. A combination of antibiotics and potential antimicrobial adjuvants, (e.g., extracellular polymeric substance (EPS)-degrading enzymes and quorum sensing inhibitors (QSI) can improve the effects of antibiotics and potentially reduce bacterial resistance). In addition, encapsulation of antimicrobials within nanoparticulate systems can improve their stability and their delivery into biofilms. Lipid nanocarriers (LNCs) have been established as having the potential to improve the efficacy of existing antibiotics in combination with antimicrobial adjuvants. Among them, liquid crystal nanoparticles (LCNPs), liposomes, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs) are promising due to their superior properties compared to traditional formulations, including their greater biocompatibility, higher drug loading capacity, drug protection from chemical or enzymatic degradation, controlled drug release, targeted delivery, ease of preparation, and scale-up feasibility. This article reviews the recent advances in developing various LNCs to co-deliver some well-studied antimicrobial adjuvants combined with antibiotics from different classes. The efficacy of various combination treatments is compared against bacterial biofilms, and synergistic therapeutics that deserve further investigation are also highlighted. This review identifies promising LNCs for the delivery of combination therapies that are in recent development. It discusses how LNC-enabled co-delivery of antibiotics and adjuvants can advance current clinical antimicrobial treatments, leading to innovative products, enabling the reuse of antibiotics, and providing opportunities for saving millions of lives from bacterial infections. Full article

(This article belongs to the Special Issue Photodynamic, Photothermal and Photoimmune Therapy and Other Antimicrobial Nanomedicine-Related Applications)

► Show Figures